



Contents lists available at ScienceDirect

Gene

journal homepage: [www.elsevier.com/locate/gene](http://www.elsevier.com/locate/gene)

## Q2 Genetic determinants in ischaemic stroke subtypes: Seven year findings and a review

Q3 Anjana Munshi <sup>a,\*</sup>, Satrupa Das <sup>b,c</sup>, Subhash Kaul <sup>d</sup>

4 <sup>a</sup> Centre for Human Genetics, School of Health Sciences, Central University of Punjab, Bathinda, Punjab, India

5 <sup>b</sup> Institute of Genetics and Hospital for Genetic Diseases, Osmania University, Begumpet, Hyderabad 500016, India

6 <sup>c</sup> Dr. NTR University of Health Sciences, Vijayawada, Andhra Pradesh, India

7 <sup>d</sup> Nizam's Institute of Medical Sciences, Punjagutta, Hyderabad 500082, India

### 8 A R T I C L E I N F O

#### 9 Article history:

10 Received 9 July 2014

11 Received in revised form 6 November 2014

12 Accepted 9 November 2014

13 Available online xxxx

#### 14 Keywords:

15 Ischaemic stroke

16 Stroke subtypes

17 TOAST classification

18 Genes

19 Polymorphisms

20

21

### 35 1. Introduction

36 Stroke has been recognised as a multi-factorial polygenic and complex disease resulting from a combination of vascular, environmental and genetic factors (Della-Morte et al., 2012). Approximately 80–90% of strokes are ischaemic (IS), which happens when a blood vessel (artery) supplying the blood to an area of the brain becomes blocked by a blood clot (Bonita, 1992; Flossmann et al., 2004; Brown et al., 1996). The role of genetic determinants in ischaemic stroke has been demonstrated in a number of reports which include twin, family and animal model studies (Wang et al., 1997). Recent technological advancements and two major international projects i.e. 'Human Genome Project' and 'HapMap Project' have tremendously contributed in the discovery of genes associated with various complex diseases. The discovery of SNPs in the first project and the development of haplotype map of human genome in the latter have greatly influenced the role of association studies in complex diseases including cardiovascular diseases and stroke. Among the several genes reported to be associated with stroke only a

### A B S T R A C T

Stroke is a global health problem and a leading cause of disability worldwide. There have been numerous studies undertaking research on different aspects of ischaemic stroke employing various epidemiological, clinical and molecular parameters. Nevertheless ischaemic stroke being a complex disorder with different subtypes demands equal attention towards its subtypes too. Since there has been enough evidence that disposition to certain subtype is genetically determined and there is a distinct mechanism that influences its development, association studies should focus on subtypes simultaneously while studying specific genes. Data from such studies will thus provide better and intricate findings with regard to heterogenous ischaemic stroke. In the present review we discuss the genes studied by our group over a period of seven years in association with stroke subtypes in a South Indian population and correlate the findings with similar genetic studies from other populations so as to provide an overview of various genes involved in the pathogenesis of ischaemic stroke subtypes.

© 2014 Published by Elsevier B.V.

few have been replicated which could be attributed to complex genetic aetiology and many loci influencing the pathophysiology of stroke. Nevertheless, the association of several identified genes with stroke still remains controversial and differences in ethnicity/race further add up to the underlying complexity of the disease, its risk and prognosis. Apart from these etiological factors ischaemic stroke is also characterised by different subtypes that have distinct pathophysiological mechanisms and different classification systems have been proposed for establishing the distinct stroke subtypes. These include The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification, Stop-Stroke Study TOAST (SSS-TOAST) classification, the Causative Classification System (CCS), A-S-C-O (A for atherosclerosis, S for small vessel disease, C for cardiac source, O for other causes) classification and OSCP (Oxfordshire Community Stroke Project) classification (Adams et al., 1993; Ay et al., 2005, 2007; Amarenco et al., 2009; Bamford et al., 1991).

Among these the TOAST classification has been extensively used in majority of the studies, and it is also the first system based on stroke mechanism and currently the most preferred one, although with certain limitations. It classifies ischaemic stroke into 5 categories: large artery atherosclerosis (occlusion or stenosis with  $\geq 50\%$  diameter reduction of a brain-supplying artery with location and morphology typical of atherosclerosis); small artery occlusion (the presence of one of the traditional lacunar syndromes – pure motor stroke, pure sensory stroke, sensory motor stroke, ataxic hemiparesis, and dysarthria-clumsy hand syndrome additionally infarction  $< 1.5$  cm of diameter or normal CT/MRI examination, the absence of acute cerebral cortical dysfunction,

Q5 Abbreviations: TOAST, The Trial of ORG 10172 in Acute Stroke Treatment; CCS, Causative Classification System; OSCP, Oxfordshire Community Stroke Project; RAAS, Renin Angiotensin Aldosterone System; CT, computed tomography; MRI, magnetic resonance imaging; LAA, large artery atherosclerosis; ILA, intracranial large artery; ELA, extracranial large artery; SAO, small artery occlusion; CE, cardioembolism; ODA, other determined aetiologies; UDA, undetermined aetiology.

\* Corresponding author.

E-mail address: [anjanadurani@yahoo.co.in](mailto:anjanadurani@yahoo.co.in) (A. Munshi).

<http://dx.doi.org/10.1016/j.gene.2014.11.015>  
0378-1119/© 2014 Published by Elsevier B.V.

Please cite this article as: Munshi, A., et al., Genetic determinants in ischaemic stroke subtypes: Seven year findings and a review, Gene (2014), <http://dx.doi.org/10.1016/j.gene.2014.11.015>

and the absence of signs of cardiac embolisms); cardio-embolism (the presence of a high- or medium-risk source of cardiac embolism); other determined aetiologies (show some rare causes of stroke e.g. non-atherosclerotic vasculopathies, hypercoagulable states or haematologic disorders, genetic disorders and metabolic disorders and moreover diagnostic procedures, including blood tests or arteriography should reveal one of the unusual causes of stroke) and stroke of undetermined aetiology. The undetermined category is a heterogeneous group with no cause found despite proper investigation. Although a recent study undertaken by Marnane et al. (2010) found both the CCS and ASCO system to be good enough when compared with TOAST, they do suggest for a feasible single combined classification system (Marnane et al., 2010). Such a system if well-established will provide a uniform platform to harmonise the heterogenous ischaemic stroke to an extent and also for optimising the stroke treatment.

The genetic contribution to multifactorial stroke is polygenic. However, identifying the underlying genes has been a major challenge. Most studies have focussed on polymorphic variants promoting stroke, predisposing phenotypes or mediators. The polyetiologic ischaemic stroke shows marked variation in its subtypes, therefore studies focusing on genetic risk factors should equally pay attention to aetiological ischaemic stroke subtypes.

Significant research is being conducted to establish the relationship between the functional variants of a number of genes including genes involved in Renin Angiotensin Aldosterone System (RAAS), homocysteine metabolising gene, nitric oxide synthase metabolising gene, lipid metabolising gene, fibrinolytic/thrombotic genes, pro-inflammatory/anti-inflammatory genes and other classes of genes. However, very few studies have evaluated the role of various candidate genes in the development of specific stroke subtypes. Therefore, in the present study we aim to document the various genes involved in progression of different stroke subtypes in a South Indian population from Andhra Pradesh and also review the genes involved in the pathogenesis of stroke subtypes reported in other populations.

## 2. Materials and methods

### 2.1. Subjects

One thousand and five hundred ischaemic stroke patients (males: females = 1069:431) presenting with new stroke evaluated in the neurology department of Nizam's Institute of Medical Sciences (NIMS), Hyderabad (A.P., India) between June 2007 and March 2014 were enrolled for the study. The study was approved by the ethical committee of the study hospital as well as the Institutional Ethical Committee. All the patients were examined by a qualified stroke neurologist and ischaemic stroke was differentiated by computed tomography (CT) scans and magnetic resonance imaging (MRI). All the patients underwent CT scan as well as MRI. Patients with major cardiac, renal, hepatic, endocrinological disorders, skeletal disorders and cancerous diseases were excluded from this study. As a control group healthy individuals matched for sex and age were recruited from the same geographic area with no clinical evidence of any cerebrovascular disease. Information on demographic characteristics and risk factors was collected using a structured questionnaire. Samples were collected only after obtaining the written informed consent. The ischaemic stroke was classified into subtypes according to the TOAST classification (Adams et al., 1993) and hypertension, alcohol use, diabetes and smoking were defined as reported previously (Munshi et al., 2008).

### 2.2. DNA isolation and genotyping

A total of 5 ml of blood was collected in EDTA tubes and genomic DNA was extracted from blood samples using standard phenol–chloroform method. The polymorphisms in various genes reported in this study were detected as reported earlier (Munshi et al., 2008, 2009a, 2009b,

2010a, 2010b, 2010c, 2010d, 2011, 2012a, 2012b, 2012c; Babu et al., 2012; Das et al., 2014a; Roy et al., 2014b; Sharma et al., 2013).

### 2.3. Statistical analysis

Hardy–Weinberg equilibrium was tested for the various gene polymorphisms and the association between genotypes and ischaemic stroke was examined by odds ratio with 95% confidence interval (CI) and chi-square analysis using Open EPI6 software (Open Epi Version 2.3.1 from the Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA). Allelic frequencies were calculated according to the number of different alleles observed and the total number of alleles examined. Statistical significance was defined as  $p < 0.05$ .

## 3. Results

A total of 1500 ischaemic stroke patients were collected over a period of seven years. The clinical characteristics of all the patients have been given in Table 1. The mean age was 54.6 years for ischaemic stroke patients and the profiles of the patients for the various risk factors revealed hypertension in 57.5%, diabetes in 47.9%, smoking in 47.1%, alcohol use in 42.8% and family history of stroke in 21.6% of patients. The distribution of patients belonging to different subtypes according to TOAST classification has been given in Table 2. A total of 669 (44.6%) patients were found to be diagnosed with large artery atherosclerosis (LAA) of which 431 (64.4%) and 238 (35.6%) patients were found to be classified as intracranial and extracranial large artery respectively (ILA and ELA). Small artery occlusion (lacunar) (SAO) was diagnosed in 232 (15.5%), cardioembolism (CE) in 206 (13.7%), other determined aetiologies (ODA) in 82 (5.5%) and undetermined aetiology (UDA) in 311 (20.7%) of ischaemic stroke patients.

We have been studying the association of various candidate genes involved in various pathways with stroke and its subtypes for the past seven years (Munshi et al., 2008, 2009a, 2009b, 2010a, 2010b, 2010c, 2010d, 2011, 2012a, 2012b, 2012c; Babu et al., 2012; Das et al. 2014a; Roy et al. 2014b; Sharma et al., 2013). In the present study we have given a holistic picture of all these genes in association with stroke subtypes and have also evaluated all the 1500 IS samples because the sample size in some of our previous studies was low (Munshi et al., 2008, 2009b, 2010a, 2010b, 2010c, 2010d, 2012b; Das et al. 2014a). The various genes found to be associated with IS subtypes from different pathways in multiple ethnicities have been depicted in Figs. 1 and 2. The different genes studied in association with IS subtypes by us have been summarised in Table 3. The genes studied in RAAS system include ACE and CYP11B2. In ACE the I/D polymorphism studied revealed a significant association with subtype ILA [ $p = 0.007$ , OR = 1.78 (95% CI; 1.05–3.03)]. On the other hand the -344C/T polymorphism of

**Table 1**  
Clinical characteristics of ischaemic stroke patients.

Characteristics	Patients (n = 1500)
Age	54.6 (16.4)
Male:female	1069:431
Systolic BP (mm Hg) (mean ± S.D.)	149 (14.8)
Diastolic BP (mm Hg) (mean ± S.D.)	90.7 (17.6)
Total cholesterol (mean ± S.D.)	198.56 (40.2)
Triglycerides (mean ± S.D.)	181.6 (39.42)
Random glucose (mean ± S.D.)	132.7 (9.4)
HDL cholesterol (mean ± S.D.)	58.3 (20.6)
Hypertension	57.5%
Diabetes	47.9%
Smoker	47.1%
Alcohol use	42.8%
Family history of stroke	21.6%

Age, systolic BP, diastolic BP, total cholesterol, high density lipoprotein (HDL) cholesterol, random glucose and triglycerides are given as mean (SD).


**Table 2**

Distribution of ischaemic stroke subtypes classified according to TOAST classification.

TOAST classification	Total no. of patients (1500)
Large artery atherosclerosis	669 (44.6%)
A) Intracranial large artery	431 (64.4%)
B) Extracranial large artery	238 (35.6%)
Small artery occlusions (lacunar)	232 (15.5%)
Cardioembolism	206 (13.7%)
Other determined aetiologies	82 (5.5%)
Undetermined aetiology	311 (20.7%)

CYP11B2 was found to be associated with ILA [ $p < 0.001$ , OR = 3.07 (95% CI; 1.55–5.95)], SAO [ $p < 0.001$ , OR = 4.00 (95% CI; 1.67–9.20)] and CE [ $p < 0.001$ , OR = 3.82 (95% CI; 1.09–9.50)]. The MTHFR gene which is involved in homocysteine metabolism, has been well studied in different ethnic populations, the C677T polymorphism of MTHFR evaluated in the study population was found to be associated with subtypes ILA [ $p < 0.05$ , OR = 1.6 (95% CI; 1.3–2.7)], SAO [ $p < 0.05$ , OR = 1.4 (95% CI; 1.12–3.01)] and UDA [ $p < 0.05$ , OR = 0.7 (95% CI; 0.28–0.95)]. The eNOS gene which plays an active role in the maintenance of vascular haemostasis was however, found not to be associated with any of the stroke subtypes. The LPL gene HindIII polymorphism which is involved in lipid metabolism was found to be associated with ILA [ $p = 0.0003$ , OR = 3.33 (95% CI; 1.54–7.23)] and SAO [ $p = 0.07$ , OR = 2.21 (95% CI; 0.92–5.59)]. The various genes studied in fibrinolytic and thrombotic genes were found to be associated with different stroke subtypes. The tPA C-7351T polymorphism showed a negative association whereas the I/D polymorphism was found to be associated with subtype ILA [ $p < 0.001$ , OR = 3.06 (95% CI; 1.68–4.73)] and UDA [ $p = 0.004$ , OR = 2.66 (95% CI; 1.35–5.05)]. However, the other two variants studied in this system i.e. PAI-1 gene, 4G/5G polymorphism and prothrombin gene G2021A polymorphism did not show a significant association with any specific stroke subtype. In pro-inflammatory/anti-inflammatory pathways G+448A polymorphism of TNF- $\alpha$  gene was found to be

associated with ILA [ $p = 0.026$ , OR = 1.77 (95% CI; 1.16–3.10)], ELA [ $p = 0.008$ , OR = 2.65 (95% CI; 1.25–5.35)], CE [ $p = 0.007$ , OR = 2.34 (95% CI; 1.25–5.22)] and UDA [ $p < 0.001$ , OR = 3.29 (95% CI; 1.60–6.05)] but -1612 5A/6A polymorphism of MMP-3 gene and G1059C variant of CRP gene did not show a significant association with IS. On the other hand G-1082A polymorphism of IL-10 was found to be associated with subtypes ELA [ $p = 0.01$ , OR = 2.76 (95% CI; 1.14–4.64)] and UDA [ $p = 0.0009$ , OR = 3.8 (95% CI; 1.92–3.59)]. E-selectin S128R polymorphism was associated significantly with subtype ILA [ $p < 0.001$ , OR = 9.39 (95% CI; 5.35–16.9)] and SAO [ $p < 0.001$ , OR = 9.61 (95% CI; 4.94–19.6)]. The -1382G polymorphism of CCL-11 gene was found to be associated with subtype ILA [ $p < 0.0001$ , OR = 9.3 (95% CI; 5.49–16.6)] and SAO [ $p < 0.0001$ , OR = 9.56 (95% CI; 4.77–19.7)]. Analysis of ALOX5AP gene for polymorphism SG13S114T/A showed association with subtype ILA [ $p < 0.001$ , OR = 2.07 (95% CI; 1.29–3.35)] and CE [ $p < 0.001$ , OR = 4.76 (95% CI; 2.9–8.5)]. Other genes which could not be grouped into particular system like CYP4F2 gene, G1347A polymorphism showed association with CE subtype of stroke [ $p < 0.001$ , OR = 4.28 (95% CI; 1.62–5.24)]. For the ESR1 gene, analysis of PvuII polymorphism showed positive association with subtypes ELA [ $p = 0.002$ , OR = 3.62 (95% CI; 1.35–5.74)], SAO [ $p = 0.0005$ , OR = 4.76 (95% CI; 2.52–9.91)], CE [ $p = 0.0003$ , OR = 3.29 (95% CI; 1.33–4.72)] and UDA [ $p = 0.012$ , OR = 3.02 (95% CI; 1.53–5.16)]. However, the other variant XbaI did not show a significant association with IS and its subtypes. For PDE4D gene SNPs 32 and 87 were reported to be negatively associated whereas, SNP 83 was found to be associated with subtypes ILA [ $p < 0.0001$ , OR = 2.95 (95% CI; 2.01–4.26)], ELA [ $p = 0.034$ , OR = 0.35 (95% CI; 0.09–1.08)] and SAO [ $p < 0.0001$ , OR = 3.08 (95% CI; 1.84–5.12)]. SNP 41 was found to be significantly associated with subtypes ILA [ $p < 0.001$ , OR = 3.16 (95% CI; 1.86–5.05)], ELA [ $p = 0.002$ , OR = 2.68 (95% CI; 1.32–5.07)], SAO [ $p = 0.029$ , OR = 2.21 (95% CI; 1.16–4.44)] and CE [ $p = 0.044$ , OR = 0.32 (95% CI; 0.18–1.06)]. On the other hand SNP 56 was found to be associated with all the subtypes ILA [ $p < 0.001$ , OR = 3.15 (95% CI; 1.9–5.55)], ELA [ $p <$

**Fig. 1.** Genes found to be associated with ischaemic stroke subtypes (TOAST classification).






Fig. 2. Various genes from different pathways reported to be associated with ischaemic stroke subtypes.

0.001, OR = 3.17 (95% CI; 1.7–6.14)] SAO [ $p < 0.001$ , OR = 4.74 (95% CI; 2.85–8.56)], ODA [ $p < 0.001$ , OR = 6.74 (95% CI; 2.76–15.36)] and UDA [ $p < 0.001$ , OR = 3.98 (95% CI; 2.75–6.67)].

#### 4. Discussion

This study by our group is a population based case–control prospective study carried over a period of seven years from 2007 to 2014 in a South Indian population from Andhra Pradesh. The association of various candidate genes with IS and its subtypes classified according to TOAST classification has been evaluated. As IS is a major cause of morbidity, mortality and an economic burden on developing countries multiple research is being carried out on different risk factors of stroke like genetic, molecular, biochemical, cytological, and epidemiological. In the present study however, we have tried to present a consolidated account of different genes studied in association with IS subtypes globally and also discuss the subtypes found to be significantly associated with different genes involved in various pathways, studied so far by us. Such a review in our opinion will convey the idea of need for increase in stroke subtype research.

##### 4.1. Renin Angiotensin Aldosterone System (RAAS) genes

###### 4.1.1. Angiotensin Converting Enzyme (ACE)

This gene plays an important role in hypertension and cerebrovascular diseases (CVD) and is involved in cardiac and vascular fibrosis (Holtz, 1993; Ruiz-Ortega et al., 2001). ACE is a rate-limiting enzyme and the most widely studied gene of this system involved in vascular remodeling and atherosclerosis (Slowik et al., 2004). Our study involving ACE gene I/D polymorphism revealed a significant association of DD genotype only with ILA (Table 3) (Munshi et al., 2008). This might be because ILA was the most frequent IS subtype in our study (Table 2). Most noted difference of the stroke registry of NIMS (the study hospital) from western registries was the predominance of ILA rather than ELA of LAA.

However, association with risk of lacunar infarction has been reported in a Japanese population with no effect in atherothrombotic and cardio-embolic infarction (Mizuno et al., 2003). Markus et al. also reported a positive association of D allele with lacunar infarction (Markus et al., 1995). In contrast to this, another study from Japan reported the association with thrombotic brain infarction (Doi et al., 1997). Similar association was also found in a study involving 29 case–control studies from China that documents the DD genotype to be a risk factor for cerebral infarction (Tao et al., 2009). A meta-analysis involving 11 studies by Rao et al., suggests the DD genotype to be a greater risk factor for small vessel when compared with large vessel disease (Rao et al., 2009). In contrast to these findings a study involving Polish population could not establish an association of this polymorphism with any of the etiological ischaemic stroke subtypes (Pera et al., 2006).

###### 4.1.2. Aldosterone synthase gene (CYP11B2)

The other well-studied gene of RAAS is aldosterone synthase gene CYP11B2. We found a positive association of -344C/T polymorphism of this gene with ILA, SAO and CE (Munshi et al., 2010a) (Table 3). Similar results were also observed by two other independent studies among Tunisian Arabs and Chinese Han population (Saidi et al., 2010; Yan and Wang, 2012). In contrast to these a recent meta-analysis by Pi et al. reports no such significant association for the polymorphism with IS (Pi et al., 2013).

Nevertheless studies focussing on other related genes from RAAS excluding ACE gene have been less and therefore a great amount of focus is needed on them.

##### 4.2. Homocysteine metabolising gene

###### 4.2.1. Methylene tetrahydrofolate reductase (MTHFR)

Elevated level of homocysteine is an independent risk factor for IS. Increasing concentration of homocysteine leads to elevated levels of S-adenosyl homocysteine which is an inhibitor for methyl transferases

t3.1 **Table 3**  
t Q1 Summary of different genes studied by us in South Indian population in ischaemic stroke subtypes.

t3.3	S. no	Gene	SNP	Association	Subtype	OR	95% CI	p value	No. of positive cases (mutants) specific to subtype (%)
t3.4	1	ACE	I/D	Positive	Intracranial large artery	1.78	(1.05–3.03)	=0.007	73 (16.9%)
t3.5	2	CYP11B2	-344C/T	Positive	Intracranial large artery	3.07	(1.55–5.95)	<0.001	212 (49.2%)
t3.6					Lacunar stroke	4.00	(1.67–9.20)	<0.001	140 (60.3%)
t3.7					Cardioembolic stroke	3.82	(1.09–9.50)	<0.001	88 (28.3%)
t3.8	3	MTHFR	C677T	Positive	Intracranial large artery	1.6	(1.3–2.7)	<0.05	21 (4.9%)
t3.9					Lacunar stroke	1.4	(1.12–3.01)	<0.05	14 (6.03%)
t3.10					Undetermined aetiology	0.7	(0.28–0.95)	<0.05	6 (1.9%)
t3.11	4	eNOS	Intron 4b/a	Positive	No specific subtype				
t3.12	5	LPL	HindIII	Positive	Intracranial large artery	3.33	(1.54–7.23)	=0.0003	240 (55.7%)
t3.13					Lacunar stroke	2.21	(0.92–5.59)	=0.07	142 (61.2%)
t3.14	6	tPA	C-7351T	Negative	Intracranial large artery	3.06	(1.68–4.73)	<0.001	86 (19.9%)
t3.15			I/D	Positive	Undetermined aetiology	2.66	(1.35–5.05)	=0.004	49 (15.7%)
t3.16	7	PAI-1	4G/5G	Negative					
t3.17	8	Prothrombin	G2021A	Negative					
t3.18	9	TNF- $\alpha$	G+448A	Positive	Intracranial large artery	1.77	(1.16–3.10)	=0.026	67 (15.5%)
t3.19					Extracranial large artery	2.65	(1.25–5.35)	=0.008	64 (26.9%)
t3.20					Cardioembolism	2.34	(1.25–5.22)	=0.007	44 (21.3%)
t3.21					Undetermined aetiology	3.29	(1.60–6.05)	<0.001	71 (22.8%)
t3.22	10	MMP-3	-1612 5A/6A	Negative					
t3.23	11	IL-10	G-1082A	Positive	Extracranial large artery	2.76	(1.14–4.64)	=0.01	68 (28.6%)
t3.24					Undetermined aetiology	3.8	(1.92–3.59)	=0.0009	84 (27%)
t3.25	12	CRP	G1059C	Negative					
t3.26	13	E-selectin	S128R	Positive	Intracranial large artery	9.39	(5.35–16.9)	<0.001	22 (5%)
t3.27					Lacunar stroke	9.61	(4.94–19.6)	<0.001	4 (1.72%)
t3.28	14	CCL-11	A-1382G	Positive	Intracranial large artery	9.3	(5.49–16.6)	<0.0001	374 (86.7%)
t3.29					Lacunar stroke	9.56	(4.77–19.7)	<0.0001	177 (76.3%)
t3.30	15	ALOX5	SG13S114	Positive	Intracranial large artery	2.07	(1.29–3.35)	<0.001	116 (26.9%)
t3.31			T/A		Cardioembolism	4.76	(2.9–8.5)	<0.001	95 (46.1%)
t3.32	16	CYP4F2	G1347A	Positive	Cardioembolic stroke	4.28	(1.62–5.24)	<0.001	92 (44.7%)
t3.33	17	ESR1	PvuII (rs2234693)	Positive	Extracranial large artery	3.62	(1.35–5.74)	=0.002	57 (23.9%)
t3.34					Lacunar stroke	4.76	(2.52–9.91)	=0.0005	47 (20.2%)
t3.35					Cardioembolism	3.29	(1.33–4.72)	=0.0003	60 (29.1%)
t3.36			XbaI (rs9340799)	Negative	Undetermined aetiology	3.02	(1.53–5.16)	=0.012	56 (18%)
t3.37	18	PDE4D	SNP 32	Negative	Intracranial large artery	2.95	(2.01–4.26)	<0.0001	87 (20.2%)
t3.38			SNP 87	Negative	Extracranial large artery	0.35	(0.09–1.08)	=0.034	9 (3.8%)
t3.39			SNP 83	Positive	Lacunar stroke	3.08	(1.84–5.12)	<0.0001	53 (22.8%)
t3.40			SNP 41	Positive	Intracranial large artery	3.16	(1.86–5.05)	<0.001	130 (30.1%)
t3.41					Extracranial large artery	2.68	(1.32–5.07)	=0.002	60 (25.2%)
t3.42					Lacunar stroke	2.21	(1.16–4.44)	=0.029	47 (20.2%)
t3.43					Cardioembolism	0.32	(0.18–1.06)	=0.044	17 (8.2%)
t3.44			SNP 56	Positive	Intracranial large artery	3.15	(1.9–5.55)	<0.001	90 (20.9%)
t3.45					Extracranial large artery	3.17	(1.7–6.14)	<0.001	55 (23.1%)
t3.46					Lacunar stroke	4.74	(2.85–8.56)	<0.001	58 (25%)
t3.47					Other determined aetiologies	6.74	(2.76–15.36)	<0.001	48 (58.5%)
t3.48					Undetermined aetiology	3.98	(2.75–6.67)	<0.001	91 (29.3%)

301 that alters methylation of genes and thus modulates gene expression  
302 changes (Yi et al., 2000). Among the genes involved in the metabolism  
303 of homocysteine, methylene tetrahydrofolate reductase (MTHFR)  
304 C677T polymorphism plays a pivotal role by decreasing the activity of  
305 MTHFR and increasing homocysteine levels (Weisberg et al., 1998).  
306 Choi et al. and They-They et al. suggest the C677T polymorphism to be  
307 a risk factor for SAO and atherothrombotic stroke respectively (Choi  
308 et al., 2003; They-They et al., 2011). A large case–control study from  
309 China also reported the polymorphism to be responsible for cerebral  
310 thrombotic stroke (Li et al., 2003). Hassan et al. document the C677T  
311 polymorphism to be associated with ischaemic leukoaraiosis (cerebral  
312 small vessel disease causing lacunar infarction) among Caucasians  
313 Q15 (Hassan et al., 2004a, 2004b). We studied polymorphism C677T in asso-  
314 ciation with IS subtypes and found the CT genotype to be a strong risk  
315 factor for ILA, SAO and UDA (unpublished data) (Table 3). Studies  
316 analysing the homocysteine metabolising genes with respect to stroke  
317 subtypes are very few since majority of the studies have focussed on ho-  
318 mocysteine levels in association with the variant genotype.

### 319 4.3. Nitric oxide synthase metabolising gene

#### 320 4.3.1. Endothelial nitric oxide synthase gene (eNOS)

321 NOS family of genes generates nitric oxide (NO) in blood vessels and  
322 regulates vascular function and maintenance of vascular homeostasis.

Reduction in the activity of vascular endothelial nitric oxide synthase  
leads to impaired endothelium dependent vasodilation that is implicat-  
ed in stroke (Stagliano et al., 1997). Our study on eNOS 4b/a variable  
number tandem repeat (VNTR) polymorphism of eNOS gene, revealed  
a significant association with IS but it did not associate with any specific  
stroke subtype (Munshi et al., 2010b) (Table 3). Study by Hassan et al.,  
involving T-786C and intron 4b/a polymorphism reported the combina-  
tion of -786C and intron 4a alleles to be protective in lacunar infarction  
suggesting this haplotype to have a particular functional role. One po-  
tential explanation suggested for this effect is that intron 4, 27-bp repeat  
element has a cis regulatory role that enhances the transcription activity  
at the -786 locus (Hassan et al., 2004a, 2004b; Wang et al., 2002) but  
contrary to this finding Hou et al. found the 4a allele to be a risk factor  
for all stroke subtypes (Hou et al., 2001). Although, we did not study  
the mutation T-786C in our samples we could not reach any conclusive  
results on IS subtype association with variant eNOS 4b/a despite being  
positive for IS.

### 340 4.4. Lipid metabolising genes

#### 341 4.4.1. Lipoprotein lipase gene (LPL)

342 Lipoprotein and lipid metabolising genes have been implicated in  
343 the pathogenesis of ischaemic, cerebrovascular diseases and atheroscle-  
344 rosis. The lipoprotein lipase (LPL) gene is known to play an important

345 role in plasma lipoprotein metabolism. We evaluated HindIII polymorph-  
 346 ism of the gene in association with stroke subtypes and a significant  
 347 association with IS subtype ILA was observed (Munshi et al., 2012a)  
 348 (Table 3). A possible explanation for this could be that SAO is due to ath-  
 349 erosclerosis, microatheroma and hemodynamic perfusion but no such  
 350 atherosclerotic role exists for CE stroke because it is due to embolism  
 351 in patients with nonvalvular arterial fibrillation (Shimo-Nakanishi  
 352 et al., 2001). The study by Shimi-Nakanishi et al., involving HindIII,  
 353 PvuII and Ser447Stop mutations documented the association of only  
 354 HindIII polymorphism with atherothrombotic cerebral infarction  
 355 (Shimo-Nakanishi et al., 2001). In contrast to this, study by Xu et al.,  
 356 among the Chinese suggested the association of PvuII polymorphism  
 357 and Ser447Stop mutation and not HindIII polymorphism with cerebral  
 358 infarction (Xu et al., 2008). However, we are yet to evaluate the PvuII  
 359 and Ser447Stop mutations in the study population.

#### 360 4.4.2. Apolipoprotein E gene (*ApoE*)

361 This gene plays a major role in lipid transport and metabolism and is  
 362 a common gene studied in neurodegenerative diseases (Eichner et al.,  
 363 Q16 2002). This glycoprotein has three isoforms 2, 3 and 4 which gives  
 364 rise to 6 genotypes. A majority of studies report 4 allele to be associated  
 365 with high LDL cholesterol levels and cardiovascular/cerebrovascular  
 366 disease (Lenzen et al., 1986; McCarron et al., 1999). There have been sig-  
 367 nificant studies evaluating the gene in different ethnicities. Lai et al. re-  
 368 ported the 3/4 genotype to be significantly associated with SAO among  
 369 the Chinese (Lai et al., 2007) whereas Kokubo et al. suggested 2 to be a  
 370 risk factor for atherothrombosis and CE (Kokubo et al., 2000). However,  
 371 a study by Kang et al. found no difference in the genotypes between LAA  
 372 and SAO (Kang and Lee, 2006). The association of apo 4 with large ves-  
 373 sel disease was also reported by Saidi et al., among the Tunisians and by  
 374 Kessler et al., among the Germans (Saidi et al., 2009; Kessler et al.,  
 375 1997). Abboud et al. from Belgium also reported the association of apo  
 376 4 genotype with intracranial atherosclerosis (Abboud et al., 2008).  
 377 However, in contrast to these findings, the large Italian cohort study by  
 378 Cerrato et al., could not establish any significant difference in the fre-  
 379 quency of apo 4 genotypes between cases and controls (Cerrato et al.,  
 380 2005). However as far as the association of ApoE gene variants with  
 381 stroke and its subtypes in the study population is concerned, the re-  
 382 search is still going on and therefore could not be included in the current  
 383 paper.

#### 384 4.5. Fibrinolytic/thrombotic genes

385 Abnormalities in fibrinolytic and thrombotic genes have been impli-  
 386 cated in atherosclerotic diseases like myocardial infarction and stroke. A  
 387 delicate interplay between these genes tremendously affects the patho-  
 388 logical process and the insult to vascular regions of brain in IS.

#### 389 4.5.1. Tissue plasminogen activator gene (*tPA*)

390 It is a serine protease and endothelium-derived tPA is the primary  
 391 mediator of local intravascular fibrinolysis. The two polymorphisms  
 392 studied by us in this gene are tPA I/D and -7351C>T. Only the former re-  
 393 vealed a positive association with IS subtypes ILA and UDA (Babu et al.,  
 394 2012) (Table 3). A recent meta-analysis also found -7351C>T to be a sig-  
 395 nificant risk factor among East Asians when compared with Caucasians  
 396 and South Asians and after stratification the association was more  
 397 prominent in LAA rather than in SAO and CE (Sun et al., 2013). However,  
 398 Jannes et al. (2004) and Geng et al. (2008) found this polymorphism to  
 399 be associated with lacunar infarction classified according to OSCP  
 400 (Oxfordshire Community Stroke Project) classification. This disparity  
 401 in association with subtypes could be attributed to different classifica-  
 402 tion systems, since TOAST classification is based on clinical symptoms  
 403 and OSCP classification system is based on initial symptoms.

#### 404 4.5.2. Plasminogen activator inhibitor type-1 (*PAI-1*) gene

405 This gene is known to regulate the function of thrombin and is the  
 406 main inhibitor for tPA. However, we could not establish an association  
 407 of 4G/5G polymorphism with stroke in our study group (Babu et al.,  
 408 2012) (Table 3) but there are reports that show positive association  
 409 with atherothrombotic stroke (Bang et al., 2001; Wiklund et al., 2005).

#### 410 4.5.3. Prothrombin gene

411 This is also called as factor II and is a vitamin-K dependent glycopro-  
 412 tein that converts fibrinogen to fibrin. The G2021A mutation in this gene  
 413 was found not to be a risk factor for IS in our population (Munshi et al.,  
 414 2009a) (Table 3) because this polymorphism is reported to be uncom-  
 415 mon among Indians (Garewal et al., 2003; Gupta et al., 2003; Ghosh  
 416 et al., 2001; Rees et al., 1999) and it also has a low prevalence among  
 417 Caucasians (Franco et al., 1998). However, a recent report by They-  
 418 They et al. suggested it to be a risk factor for large artery stroke subtype  
 419 among Moroccans (They-They et al., 2012).

#### 420 4.6. Pro-inflammatory/anti-inflammatory genes

#### 421 4.6.1. Tumour necrosis factor- $\alpha$ (*TNF- $\alpha$* )

422 This is a potent pro-inflammatory cytokine implicated in stroke  
 423 (Feuerstein et al., 1994). Our study involving the +448G/A variant re-  
 424 vealed significant association with subtypes ILA, ELA, CE and UDA  
 425 (Munshi et al., 2011) (Table 3) but there are hardly any other reports  
 426 on the role of TNF- $\alpha$  gene variants in association with stroke subtypes.

#### 427 4.6.2. Matrix metalloproteinases (*MMPs*)

428 MMPs are a family of zinc dependent proteinases that mediate re-  
 429 modelling, capillary permeability and play an important role in tissue  
 430 and vascular homeostasis (Nagase and Woessner, 1999). MMP-3 or  
 431 stromelysin-1 gene variant -1612 (5A/6A) studied by our group was  
 432 not found to be associated with IS in our population (Munshi et al.,  
 433 2011) (Table 3). This is in accordance with a study by Kaplan et al.  
 434 (2008). However, there are reports that suggest this polymorphism to  
 435 be significantly associated with atherosclerotic cerebral infarction and  
 436 LAA among the Chinese (Huang et al., 2008; Ma et al., 2013).

#### 437 4.6.3. Interleukin 10 (*IL-10*)

438 IL-10 is a multifunctional anti-inflammatory cytokine and is known  
 439 to counterbalance the harmful effects of TNF- $\alpha$  and other pro-  
 440 inflammatory molecules (Perini et al., 2001). -1082G/A variant studied  
 441 by us revealed the A allele to be an important risk factor for IS and asso-  
 442 ciated significantly with ELA and UDA (Munshi et al., 2010c) (Table 3).  
 443 However, we did not find any other study reporting its association  
 444 with stroke subtypes.

#### 445 4.6.4. C-reactive protein (*CRP*)

446 CRP is an acute phase reactant and its levels increase pronouncingly  
 447 after tissue injury or inflammation. A lot of studies have concentrated on  
 448 the levels of CRP in IS and its subtypes but there are very few reports  
 449 studying its variants associated with stroke. Our study on 1059G>C  
 450 polymorphism revealed no mutants among controls and IS patients  
 451 (Das et al., 2014) (Table 3). A study evaluating association of this variant  
 452 with venous thromboembolism (VTE) in Chinese Han population also  
 453 found no significant difference in alleles among cases and controls  
 454 (Mahemuti et al., 2012).

#### 455 4.6.5. E-selectin (*E-sel*)

456 E-selectin is known to mediate leukocyte activation that travels  
 457 across endothelial cells, reaches brain parenchyma, triggers other in-  
 458 flammatory mediators and damages the vascular regions of the brain  
 459 (Kozuka et al., 2002). The S128R variant of the gene is known to provide  
 460 a link for the development of diseases like atherosclerosis and stroke  
 461 (Rao et al., 2002). Our study involving this variant found a significant as-  
 462 sociation with ILA and SAO subtypes (Roy et al., 2014) (Table 3).



463 However, studies on E-selectin variants in association with IS and its  
464 subtypes are negligible.

#### 465 4.6.6. Eotaxin-1 (CCL-11)

466 Eotaxin-1 acts as a chemoattractant for leukocytes and directs them  
467 towards site of inflammation (Chalouhi et al., 2013). The -1382A>G var-  
468 iant studied by us revealed a significant association with IS subtypes ILA  
469 and SAO stroke (Unpublished data) (Table 3). A study among Chinese  
470 involving various variants of CCL-11 gene suggested a strong association  
471 of this variant with IS (Zhao et al., 2012) but there are no reports on its  
472 association with IS subtypes.

#### 473 4.6.7. Arachidonate 5-lipoxygenase activating protein (ALOX5AP)

474 This gene is a main regulator for the synthesis of leukotrienes which  
475 are secreted by inflammatory cells at the injured sites and thus plays an  
476 important role in atherosclerosis and other vascular damages  
477 (Spanbroek et al., 2003). Evaluating the association of SG13S114T/A  
478 variant of ALOX5AP1 gene with IS and its subtypes, we found significant  
479 association with ILA and CE (Sharma et al., 2013) (Table 3). Zhang et al.  
480 reported a 1.62 fold increase in thrombotic stroke among the patients  
481 having SG13S114AA genotype (Zhang et al., 2012).

#### 482 4.7. Other genes

##### 483 4.7.1. Cytochrome P450 (CYP) gene

484 CYP4F2 gene is a subfamily of CYP450 enzymes and is involved in  
485 the metabolism of 20-hydroxyeicosatetraenoic acid (20-HETE). 20-  
486 HETE is a potent vasoconstrictor involved in the constriction of cerebral  
487 blood vessel and is involved in the pathogenesis of IS and its subtypes  
488 (Deng et al., 2010). Very few studies have been carried out evaluating  
489 its association with IS. Our study revealed significant association with  
490 CE stroke in our population (Munshi et al., 2012b) (Table 3) however,  
491 there are no studies evaluating its role in IS subtypes.

##### 492 4.7.2. Oestrogen receptor- $\alpha$ (ESR1)

493 Oestrogen, a sex steroid influences reproductive, cardiovascular and  
494 skeletal systems in both men and women by binding to specific  
495 oestrogen receptors of target cells (Deroo and Korach, 2006). The eval-  
496 uation of ESR1 PvuII (-397T/C) and XbaI (-351A/G) polymorphisms by  
497 Molvarec et al., Markoula et al. and Kunnas et al., did not find any asso-  
498 ciation among ischaemic stroke or its subtypes in both the genders  
499 (Molvarec et al., 2007; Markoula et al., 2008; Kunnas et al., 2010). Our  
500 study however, found a positive association of the pp genotype of  
501 PvuII in both women and men afflicted with stroke but could not estab-  
502 lish the same for the XbaI variant (Munshi et al., 2010d). Significant as-  
503 sociation was also established by us in stroke subtypes ELA, SAO, CE and  
504 UDA (Table 3). However studies by Zhang et al. and Shearman et al., re-  
505 ported the TC and CC genotypes to be associated with stroke respective-  
506 ly (Zhang et al., 2002; Shearman et al., 2005). A recent meta-analysis too  
507 supports the association of only PvuII variant and not XbaI with stroke  
508 but none of the studies have evaluated association of ESR1 gene variants  
509 with stroke subtypes (Li et al., 2012).

##### 510 4.7.3. Phosphodiesterase 4D (PDE4D)

511 This gene belongs to a superfamily of phosphodiesterases (PDE4  
512 family) that is implicated in the degradation of cyclic adenosine  
513 monophosphate (cAMP) and cyclic guanosine monophosphate  
514 (cGMP) and codes for cAMP specific 3' 5'-cyclic phosphodiesterase 4D  
515 which has indirect effects on cardiovascular and stroke biomarkers  
516 (Worrall and Mychaleckyj, 2006; Schubert et al., 2000). After  
517 Gretarsdottir et al., recognised this gene and its SNPs 83, 32 and 87 to  
518 be independent risk factors for stroke, a dozen of studies comprising  
519 of cohorts from different ethnicities have studied its various SNPs in  
520 PDE4D gene in association with stroke (Gretarsdottir et al., 2003). The  
521 study by our group involving SNPs 83, 32, 87, 41, and 56 and a novel  
522 SNP at position 59736747T>G revealed SNPs 83, 41 and 56 to be

significantly associated with IS and its subtypes (Munshi et al., 2009b, 523  
2012c). SNP 83 in our study was found to be associated with ILA, ELA 524  
and SAO subtypes (Table 3) whereas it was found to be associated 525  
with CE stroke in an American population (Meschia et al., 2005). SNP 526  
87 on the other hand was found to be associated with CE stroke 527  
among both blacks and whites by Woo et al. (2006). The meta- 528  
analysis carried out by Bevan et al., although did not find significant as- 529  
sociation of SNP 56 but they did report its association with CE (Bevan 530  
et al., 2008) whereas Gretarsdottir et al., in Icelandic population report- 531  
ed SNP 56 to be associated with stroke of UDA (Gretarsdottir et al., 532  
2003). Further, SNP 41 was reported to be associated with ILA, ELA, la- 533  
cunar stroke and CE while SNP 56 was positively associated with ILA, 534  
ELA, lacunar stroke, ODA and UDA in our study (Table 3). 535

#### 482 4.8. Less studied genes 536

##### 483 4.8.1. Transforming growth factor $\beta$ 1 gene (TGF- $\beta$ 1) 537

538 With regard to stroke subtypes we found only one study that sug- 539  
gests the C869T variant to be strongly associated with small vessel oc- 540  
clusion (SVO) particularly among the females (Kim and Lee, 2006). 540

##### 484 4.8.2. Neuropeptide Y gene (NPY) 541

542 The study by Lee et al., suggested the C4112T variant to be associated 542  
with LAA and the haplotype TA or CC of C4112T and A6411C variants to 543  
be associated with LAA and SVO among the other subtypes (Lee and 544  
Kong, 2007). 545

##### 485 4.8.3. Oxidative phosphorylation gene (OXPHOS) 546

547 The study by Anderson et al., in IS and its subtypes reports the genes 547  
from complexes I and IV of OXPHOS to be associated with SVO 548  
(Anderson et al., 2013). 549

##### 486 4.8.4. Epoxide hydrolase gene (EPHX2) 550

551 This gene was found to be associated with large vessel disease and 551  
stroke of UDA (Gschwendtner et al., 2008). 552

##### 487 4.8.5. Protein C gene (PROC) 553

554 A three-nucleotide duplication/deletion variant (c.574\_576del) was 554  
identified and was found to be significantly associated with IS and its 555  
subtypes SAO and CE stroke by Lu et al. (2013). 556

##### 488 4.8.6. Thromboxane A2 receptor gene (TXA2R) 557

558 The study by Zhao et al., among the Chinese showed the rs768963 to 558  
be significantly associated with LAA (Zhao et al., 2013). 559

##### 489 4.8.7. Genome wide association studies suggested genes 560

561 The Genome Wide Association Studies (GWAS) have suggested 561  
paired-like homeodomain transcription factor 2 (PITX2) and zinc finger 562  
homeobox 3 (ZFHX3) to be associated with CE which could be due to as- 563  
sociation of these loci with atrial fibrillation responsible for cardiac em- 564  
bolism (Gretarsdottir et al., 2008a, 2008b; Gudbjartsson et al., 2009). Q17  
Additionally the GWAS by International Stroke Genetics Consortium 566  
(ISGC) and Wellcome Trust Case Control Consortium 2 (WTCCC2) 567  
found histone deacetylase 9 (HDAC9) within chromosome 7p21 to be 568  
associated with large vessel stroke (Bellenguez et al., 2012). Further, a Q18  
locus on chromosome 9p21 and the rs1906591 variant on chromosome 570  
4q25 have been suggested to be associated with large vessel disease and 571  
CE subtype respectively (Gschwendtner et al., 2009; Lemmens et al., 572  
2010; Gretarsdottir et al., 2008a, 2008b). 573

## 574 5. Conclusion 574

575 Since stroke has been classified as a complex disorder, deciphering 575  
the exact cause of stroke has proved to be complicated. Stroke research 576  
has provided us with extensive knowledge on roles of several substan- 577  
tial candidate genes however, a clear picture still remains unestablished. 578

Further the different subtypes in IS which have a genetic predisposition too, fuels up the complexity of the disease. Though a positive association for various genes with IS have been reported, they however, do not focus on subtypes of IS and therefore, a limited information is available with respect to the role of genetic variation associated with stroke subtypes. Majority of the genes studied by our group show association with ILA among South Indians (Asians) which could be due to large amount of ILA patients in the population. This observation can be justified by the difference in the distribution of carotid atherosclerosis which has a racial/geographical tendency. It is known that Caucasians are more prone to extracranial atherosclerosis whereas among Asians and blacks intracranial atherosclerosis is common. However, Kumar et al., found the distribution of atherosclerosis among Indians to be midway between Asians and Caucasians (Kumar et al., 2010). Further, the underlying reason for the association of specific gene with specific stroke subtype is also currently unknown.

In conclusion, we propose that genetic association studies in IS can well contribute to the understanding of distribution of IS subtypes in different ethnicities globally. Such outcomes can substantially contribute in better understanding of pathophysiology of IS and help in pharmacogenetic research of stroke, thus providing new therapeutic targets and better protection from damages caused due to IS. The genetics of IS subtypes is one of most promising research frontiers and the identification of molecular biomarkers of preclinical IS subtypes will alert the individuals who are at the highest risk. This will eventually lead to novel therapeutic approaches for IS and its subtypes.

## Conflict of interest

None declared.

## Q19 Uncited references

DiMauro and Schon, 2008  
 Dobolyi et al., 2012  
 International Stroke Genetics Consortium (ISGC) et al., 2012  
 Michel and Rascher, 1995  
 Wei et al., 2007

## References

- Abboud, S., Viiri, L.E., Lu'jtjohann, D., Goebeler, S., Luoto, T., Friedrichs, S., Desfontaines, P., Gazagnes, M.D., Laloux, P., Peeters, A., Seeldrayers, P., Lehtimäki, T., Karhunen, P., Pandolfo, M., Laaksonen, R., 2008. Associations of apolipoprotein E gene with ischemic stroke and intracranial atherosclerosis. *Eur. J. Hum. Genet.* 16, 955–960.
- Adams Jr., H.P., Bendixen, B.H., Kappelle, L.J., Biller, J., Love, B.B., Gordon, D.L., Marsh III, E.E., 1993. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST Trial of Org 10172 in Acute Stroke Treatment. *Stroke* 24, 35–41.
- Amarenco, P., Bogousslavsky, J., Caplan, L.R., Donnan, G.A., Hennerici, M.G., 2009. New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. *Cerebrovasc. Dis.* 27, 502–508.
- Anderson, C.D., Biffi, A., Nalls, M.A., Devan, W.J., Schwab, K., Ayres, A.M., Valant, V., Ross, O.A., Rost, N.S., Saxena, R., Viswanathan, A., Worrall, B.B., Brott, T.G., Goldstein, J.N., Brown, D., Broderick, J.P., Norrving, B., Greenberg, S.M., Silliman, S.L., Hansen, B.M., Tirschwell, D.L., Lindgren, A., Slowik, A., Schmidt, R., Selim, M., Roquer, J., Montaner, J., Singleton, A.B., Kidwell, C.S., Woo, D., Furie, K.L., Meschia, J.F., Rosand, J., 2013. Common variants within oxidative phosphorylation genes influence risk of ischemic stroke and intracerebral hemorrhage. *Stroke* 44, 612–619.
- Ay, H., Furie, K.L., Singhal, A., Smith, W.S., Sorensen, A.G., Koroshetz, W.J., 2005. An evidence-based causative classification system for acute ischemic stroke. *Ann. Neurol.* 58, 688–697.
- Ay, H., Benner, T., Arsava, E.M., Furie, K.L., Singhal, A.B., Jensen, M.B., Ayata, C., Towfighi, A., Smith, E.E., Chong, J.Y., Koroshetz, W.J., Sorensen, A.G., 2007. A computerized algorithm for etiologic classification of ischaemic stroke: the Causative Classification of Stroke System. *Stroke* 38, 2979–2984.
- Babu, M.S., Prabha, T.S., Kaul, S., Al-Hazzani, A., Shafi, G., Roy, S., Balakrishna, N., Jyothy, A., Munshi, A., 2012. Association of genetic variants of fibrinolytic system with stroke and stroke subtypes. *Gene* 495, 76–80.
- Bamford, J., Sandercock, P., Dennis, M., Burn, J., Warlow, C., 1991. Classification and natural history of clinically identifiable subtypes of cerebral infarction. *Lancet* 337, 1521–1526.
- Bang, C.O., Park, H.K., Ahn, M.Y., Shin, H.K., Hwang, K.Y., Hong, S.Y., 2001. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion

- polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. *Cerebrovasc. Dis.* 11, 294–299.
- Bevan, S., Dichgans, M., Gschwendtner, A., Kuhlenbäumer, G., Ringelstein, E.B., Markus, H.S., 2008. Variation in the PDE4D gene and ischemic stroke risk: a systematic review and meta-analysis on 5200 cases and 6600 controls. *Stroke* 39, 1966–1971.
- Bonita, R., 1992. Epidemiology of stroke. *Lancet* 339, 342–344.
- Brown, R.D., Whisnant, J.P., Sicks, J.D., O'Fallon, W.M., Wiebers, D.O., 1996. Stroke incidence, prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. *Stroke* 27, 373–380.
- Cerrato, P., Baima, C., Grasso, M., Lentini, A., Bosco, G., Cassader, M., Gambino, R., Cavallo Perin, P., Pagano, G., Fornengo, P., Imperiale, D., Bergamasco, B., Bruno, G., 2005. Apolipoprotein E polymorphism and stroke subtypes in an Italian cohort. *Cerebrovasc. Dis.* 20, 264–269.
- Chalouhi, N., Points, L., Pierce, G.L., Ballas, Z., Jabbour, P., Hasan, D., 2013. Localized increase of chemokines in the lumen of human cerebral aneurysms. *Stroke* 44, 2594–2597.
- Choi, B.O., Kim, N.K., Kim, S.H., Kang, M.S., Lee, S., Ahn, J.Y., Kim, O.J., Kim, S., Oh, D., 2003. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. *Thromb. Res.* 111, 39–44.
- Das, S., Roy, S., Kaul, S., Jyothy, A., Munshi, A., 2014. CRP gene (1059G>C) polymorphism and its plasma levels in ischemic stroke and hemorrhagic stroke in a South Indian population. *Inflammation* (Epub ahead of print).
- Della-Morte, D., Guadagni, F., Palmirotta, R., Testa, G., Caso, V., Paciaroni, M., Abete, P., Rengo, F., Ferroni, P., Sacco, R.L., Rundek, T., 2012. Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments. *Pharmacogenomics* 13, 595–613.
- Deng, S., Zhu, G., Liu, F., Zhang, H., Qin, X., Li, L., Zhiyi, H., 2010. CYP4F2 gene V433M polymorphism is associated with ischemic stroke in the male Northern Chinese Han population. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 34, 664–668.
- Deroo, B.J., Korach, K.S., 2006. Estrogen receptors and human disease. *J. Clin. Invest.* 116, 561–570.
- DiMauro, S., Schon, E.A., 2008. Mitochondrial disorders in the nervous system. *Annu. Rev. Neurosci.* 31, 91–123.
- Dobolyi, A., Vincze, C., Pal, G., Lovas, G., 2012. The neuroprotective functions of transforming growth factor beta proteins. *Int. J. Mol. Sci.* 13, 8219–8258.
- Doi, Y., Yoshinari, M., Yoshizumi, H., Ibayashi, S., Wakisaka, M., Fujishima, M., 1997. Polymorphism of the human angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. *Atherosclerosis* 132, 145–150.
- Eichner, J.E., Dunn, S.T., Perveen, G., Thompson, D.M., Stewart, K.E., Stroehla, B.C., 2002. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. *Am. J. Epidemiol.* 155, 487–495.
- Feuerstein, G.Z., Liu, T., Barone, F.C., 1994. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. *Cerebrovasc. Brain Metab. Rev.* 6, 341–360.
- Flossmann, E., Schulz, U.G., Rothwell, P.M., 2004. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. *Stroke* 35, 212–227.
- Franco, R.F., Santos, S.E., Elion, J., Tavella, M.H., Zago, M.A., 1998. Prevalence of the G20210A polymorphism in the 3'-untranslated region of the prothrombin gene in different human populations. *Acta Haematol.* 100, 9–12.
- Garewal, G., Das, R., Ahluwalia, J., Mittal, N., Varma, S., 2003. Prothrombin G20210A is not prevalent in North India. *J. Thromb. Haemost.* 1, 2253–2254.
- Geng, Z., Sun, X.J., Shen, J., Chen, J.J., Duan, H., 2008. The study of tissue plasminogen activator -7351C/T enhancer polymorphism on the risk of cerebral infarction. *Chin. J. Clin. Neurosci.* 16, 134–138.
- Ghosh, K., Shetty, S., Madkaikar, M., Pawar, A., Nair, S., Khare, A., Pathare, A., Jijina, F., Mohanty, D., 2001. Venous thromboembolism in young patients from western India: a study. *Clin. Appl. Thromb. Hemost.* 7, 158–165.
- Gretarsdottir, S., Thorleifsson, G., Reynisdottir, S.T., Manolescu, A., Jonsdottir, S., Jonsdottir, T., Gudmundsdottir, T., Bjarnadottir, S.M., Einarsson, O.B., Gudjónsdottir, H.M., Hawkins, M., Gudmundsson, G., Gudmundsdottir, H., Andrason, H., Gudmundsdottir, A.S., Sigurdardottir, M., Chou, T.T., Nahmias, J., Goss, S., Sveinbjörnsdottir, S., Valdimarsson, E.M., Jakobsen, F., Agnarsson, U., Gudnason, V., Thorgeirsson, G., Fingerle, J., Gurney, M., Gudbjartsson, D., Frigge, M.L., Kong, A., Stefansson, K., Gulcher, J.R., 2003. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. *Nat. Genet.* 35, 131–138.
- Gretarsdottir, S., Thorleifsson, G., Manolescu, A., et al., 2008a. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. *Ann. Neurol.* 64, 402–409.
- Gretarsdottir, S., Thorleifsson, G., Manolescu, A., Styrkarsdottir, U., Helgadóttir, A., Gschwendtner, A., Kostulas, K., Kuhlenbäumer, G., Bevan, S., Jonsdottir, T., Bjarnason, H., Saemundsdottir, J., Palsson, S., Arnar, D.O., Holm, H., Thorgeirsson, G., Valdimarsson, E.M., Sveinbjörnsdottir, S., Gieger, C., Berger, K., Wichmann, H.E., Hillert, J., Markus, H., Gulcher, J.R., Ringelstein, E.B., Kong, A., Dichgans, M., Gudbjartsson, D.F., Thorsteinsdottir, U., Stefansson, K., 2008b. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. *Ann. Neurol.* 64, 402–409.
- Gschwendtner, A., Ripke, S., Freilinger, T., Lichtner, P., Müller-Myhsok, B., Wichmann, H.E., Meitinger, T., Dichgans, M., 2008. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans. *Stroke* 39, 1593–1596.
- Gschwendtner, A., Bevan, S., Cole, J.W., Plourde, A., Matarin, M., Ross-Adams, H., Meitinger, T., Wichmann, E., Mitchell, B.D., Furie, K., Slowik, A., Rich, S.S., Syme, P.D., MacLeod, M.J., Meschia, J.F., Rosand, J., Kittner, S.J., Markus, H.S., Müller-Myhsok, B., Dichgans, M., International Stroke Genetics Consortium, 2009. Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. *Ann. Neurol.* 65, 531–539.
- Gudbjartsson, D.F., Holm, H., Gretarsdottir, S., Thorleifsson, G., Walters, G.B., Thorgeirsson, G., Gulcher, J., Mathiesen, E.B., Njølstad, I., Nyrnes, A., Wilsgaard, T., Hald, E.M., Hveem, 731



- 732 K, Stoltenberg, C., Kucera, G., Stubblefield, T., Carter, S., Roden, D., Ng, M.C., Baum, L.,  
733 So, W.Y., Wong, K.S., Chan, J.C., Gieger, C., Wichmann, H.E., Gschwendtner, A.,  
734 Dichgans, M., Kuhnlebaumer, G., Berger, K., Ringelstein, E.B., Bevan, S., Markus, H.S.,  
735 Kostulas, K., Hillert, J., Sveinbjörnsdóttir, S., Valdimarsson, E.M., Løchen, M.L., Ma,  
736 R.C., Darbar, D., Kong, A., Armar, D.O., Thorsteinsdóttir, U., Stefansson, K., 2009. A se-  
737 quence variant in ZFXH3 on 16q22 associates with atrial fibrillation and ischemic  
738 stroke. *Nat. Genet.* 41, 876–878.
- 739 Gupta, N., Khan, F., Tripathi, M., Singh, V.P., Tewari, S., Ramesh, V., Sinha, N., Agrawal, S.,  
740 2003. Absence of factor V Leiden (G1691A) mutation, FII G20210A allele in coronary  
741 artery disease in North India. *Indian J. Med. Sci.* 57, 535–542.
- 742 Hassan, A., Hunt, B.J., O'Sullivan, M., Bell, R., D'Souza, R., Jeffery, S., Bamford, J.M., Markus,  
743 H.S., 2004a. Homocysteine is a risk factor for cerebral small vessel disease, acting via  
744 endothelial dysfunction. *Brain* 127, 212–219.
- 745 Hassan, A., Gormley, K., O'Sullivan, M., Knight, J., Sham, P., Vallance, P., Bamford, J.,  
746 Markus, H., 2004b. Endothelial nitric oxide gene haplotypes and risk of cerebral  
747 small-vessel disease. *Stroke* 35, 654–659.
- 748 Holtz, J., 1993. Pathophysiology of heart failure and the renin-angiotensin-system. *Basic*  
749 *Res. Cardiol.* 88, 183–201.
- 750 Hou, L., Osei-Hyiaman, D., Yu, H., Ren, Z., Zhang, Z., Wang, B., Harada, S., 2001. Association  
751 of a 27-bp repeat polymorphism in eNOS gene with ischemic stroke in Chinese pa-  
752 tients. *Neurology* 56, 490–496.
- 753 Huang, X., Zhu, M., Jin, X., Zhang, D., Wang, L., Ye, Z., 2008. Association of matrix  
754 metalloproteinase-3 serum level and the promoter 5A/6A polymorphism of the  
755 MMP-3 gene with atherosclerotic cerebral infarction. *Zhonghua Yi Xue Yi Chuan*  
756 *Xue Za Zhi* 25, 653–656.
- 757 International Stroke Genetics Consortium (ISGC), Wellcome TrustCase Control  
758 Consortium 2 (WTCCC2), Bellenguez, C., Bevan, S., Gschwendtner, A., Spencer, C.C.,  
759 Burgess, A.L., Pirinen, M., Jackson, C.A., Traylor, M., Strange, A., Su, Z., Band, G., Syme,  
760 P.D., Malik, R., Pera, J., Norrvig, B., Lemmens, R., Freeman, C., Schanz, R., James, T.,  
761 Poole, D., Murphy, L., Segal, H., Cortellini, L., Cheng, Y.C., Woo, D., Nalls, M.A.,  
762 Müller-Miyhok, B., Meisinger, C., Seedorf, U., Ross-Adams, H., Boonen, S.,  
763 Wloch-Kopec, D., Valant, V., Slark, J., Furie, K., Delavaran, H., Langford, C.,  
764 Deloukas, P., Edkins, S., Hunt, S., Gray, E., Dronov, S., Peltonen, L., Gretarsdottir,  
765 S., Thorleifsson, G., Thorsteinsdóttir, U., Stefansson, K., Boncoraglio, G.B., Parati, E.A.,  
766 Attia, J., Holliday, E., Levi, C., Franzosi, M.G., Goel, A., Helgadottir, A., Blackwell, J.M.,  
767 Bramon, E., Brown, M.A., Casas, J.P., Corvin, A., Duncanson, A., Jankowski, J., Mathew,  
768 C.G., Palmer, C.N., Plomin, R., Rautanen, A., Sawcer, S.J., Trembath, R.C., Viswanathan,  
769 A.C., Wood, N.W., Worrall, B.B., Kittner, S.J., Mitchell, B.D., Kissela, B., Meschia, J.F.,  
770 Thijs, V., Lindgren, A., Macleod, M.J., Slowik, A., Walters, M., Rosand, J., Sharma, P.,  
771 Farrall, M., Sudlow, C.L., Rothwell, P.M., Dichgans, M., Donnelly, P., Markus, H.S.,  
772 2012. Genome-wide association study identifies a variant in HDAC9 associated with  
773 large vessel ischemic stroke. *Nat. Genet.* 44, 328–333.
- 774 Jannes, J., Hamilton-Bruce, M.A., Pilotto, L., Smith, B.J., Mullighan, C.G., Barty, P.G., Koblar,  
775 S.A., 2004. Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk  
776 factor for lacunar stroke. *Stroke* 35, 1090–1094.
- 777 Kang, S.Y., Lee, W.I., 2006. Apolipoprotein E polymorphism in ischemic stroke patients  
778 with different pathogenetic origins. *Korean J. Lab. Med.* 26, 210–216.
- 779 Kaplan, R.C., Smith, N.L., Zucker, S., Heckbert, S.R., Rice, K., Psaty, B.M., 2008. Matrix  
780 metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, is-  
781 chemic stroke and hemorrhagic stroke. *Atherosclerosis* 201, 130–137.
- 782 Kessler, C., Spitzer, C., Stauske, D., Mende, S., Stadtmüller, J., Walther, R., Rettig, R., 1997.  
783 The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associat-  
784 ed with ischemic stroke involving large-vessel disease. *Arterioscler. Thromb. Vasc.*  
785 *Biol.* 17, 2880–2884.
- 786 Kim, Y., Lee, C., 2006. The gene encoding transforming growth factor beta 1 confers risk of  
787 ischemic stroke and vascular dementia. *Stroke* 37, 2843–2845.
- 788 Kokubo, Y., Chowdhury, A.H., Date, C., Yokoyama, T., Sobue, H., Tanaka, H., 2000. Age-  
789 dependent association of apolipoprotein E genotypes with stroke subtypes in a  
790 Japanese rural population. *Stroke* 31, 1299–1306.
- 791 Kozuka, K., Kohriyama, T., Nomura, E., Ikeda, J., Kajikawa, H., Nakamura, S., 2002. Endothelial  
792 markers and adhesion molecules in acute ischemic stroke-sequential change and  
793 differences in stroke subtype. *Atherosclerosis* 161, 161–168.
- 794 Kumar, G., Kalita, J., Kumar, B., Bansal, V., Jain, S.K., Misra, U., 2010. Magnetic resonance  
795 angiography findings in patients with ischemic stroke from North India. *J. Stroke*  
796 *Cerebrovasc. Dis.* 19, 146–152.
- 797 Kunnas, T., Silander, K., Karvanen, J., Valkeapää, M., Salomaa, V., Nikkari, S., 2010. ESR1  
798 genetic variants, haplotypes and the risk of coronary heart disease and ischemic stroke  
799 in the Finnish population: a prospective follow-up study. *Atherosclerosis* 211,  
800 200–202.
- 801 Lai, C.L., Liu, C.K., Lin, R.T., Tai, C.T., 2007. Association of apolipoprotein e polymorphism  
802 with ischemic stroke subtypes in Taiwan. *Kaohsiung J. Med. Sci.* 23, 491–497.
- 803 Lee, C., Kong, M., 2007. An interactive association of common sequence variants in the  
804 neuropeptide Y gene with susceptibility to ischemic stroke. *Stroke* 38, 2663–2669.
- 805 Lemmens, R., Buyschaert, I., Geelen, V., Fernandez-Cadenas, I., Montaner, J., Schmidt, H.,  
806 Schmidt, R., Attia, J., Maguire, J., Levi, C., Jood, K., Blomstrand, C., Jern, C., Wnuk, M.,  
807 Slowik, A., Lambrechts, D., Thijs, V., 2010. The association of the 4q25 susceptibility  
808 variant for atrial fibrillation with stroke is limited to stroke of cardioembolic etiology.  
809 *Stroke* 41, 1850–1857.
- 810 Lenzen, H.J., Assmann, G., Buchwalsky, R., Schulte, H., 1986. Association of apolipoprotein  
811 E polymorphism, low density lipoprotein, and coronary artery disease. *Clin. Chem.*  
812 *32*, 778–781.
- 813 Li, Z., Sun, L., Zhang, H., Liao, Y., Wang, D., Zhao, B., Zhu, Z., Zhao, J., Ma, A., Han, Y., Wang, Y.,  
814 Shi, Y., Ye, J., Hui, R., Multicenter Case-Control Study in China, 2003. Elevated plasma  
815 homocysteine was associated with hemorrhagic and ischemic stroke, but methylene-  
816 tetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic  
817 stroke. *Stroke* 34, 2085–2090.
- 818 Li, B.H., Zhang, L.L., Yin, Y.W., Pi, Y., Guo, L., Yang, Q.W., Gao, C.Y., Fang, C.Q., Wang, J.Z.,  
819 Xiang, J., Li, J.C., 2012. Association between estrogen receptor alpha c.454-397T>C  
820 and c.454-351A>G and ischemic stroke risk: a systematic review and meta-analysis.  
821 *Mol. Biol. Rep.* 39, 9331–9338.
- 822 Lu, X., Tang, L., Xu, K., Ma, J., Guo, T., Mei, H., Yang, R., Yu, J., Wang, Q., Yang, Y., Jian, X., Hu,  
823 Y., 2013. Novel association of a PROC variant with ischemic stroke in a Chinese Han  
824 population. *Hum. Genet.* 132, 69–77.
- 825 Ma, A.J., Fan, L.Y., Li, W.J., Zhao, H.Q., Han, Y., Jiang, X.S., Yi, P., Li, C.L., Song, S., Ma, C.L., Yao,  
826 R.Y., Pan, X.D., 2013. Association of matrix metalloproteinase-3 gene polymorphisms  
827 with subtypes of ischemic stroke. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 30, 461–466.
- 828 Mahemuti, A., Abudurehman, K., Aihemaiti, X., Hu, X.M., Xia, Y.N., Tang, B.P., Upur, H.,  
829 2012. Association of interleukin-6 and C-reactive protein genetic polymorphisms  
830 levels with venous thromboembolism. *Chin. Med. J.* 125, 3997–4002.
- 831 Markoula, S., Xita, N., Lazaros, L., Giannopoulos, S., Kyritsis, A.P., Georgiou, I., 2008. Estro-  
832 gen receptor  $\alpha$  gene haplotypes and diplotypes in the risk of stroke. *Stroke* 39,  
833 e172–e173.
- 834 Markus, H.S., Barley, J., Lunt, R., Bland, M., Jeffery, S., Carter, N.D., Brown, M.M., 1995.  
835 Angiotensin-converting enzyme gene deletion polymorphism: a new risk factor for  
836 lacunar stroke but not carotid atheroma. *Stroke* 26, 1329–1333.
- 837 Marnane, M., Duggan, C.A., Sheehan, O.C., Merwick, A., Hannon, N., Curtin, D., Harris, D.,  
838 Williams, E.B., Horgan, G., Kyne, L., McCormack, P.M., Duggan, J., Moore, A.,  
839 Williams, O'Connell, G., Kelly, P.J., 2010. Stroke subtype classification to mechanism-  
840 specific and undetermined categories by TOAST, A-S-C-O, and causative classification  
841 system: direct comparison in the North Dublin population stroke study. *Stroke* 41,  
842 1579–1586.
- 843 McCarron, M.O., Delong, D., Alberts, M.J., 1999. Apolipoprotein E genotype as a risk factor  
844 for ischemic cerebrovascular disease: a meta-analysis. *Neurology* 53, 1308–1311.
- 845 Meschia, J.F., Brott, T.G., Brown Jr., R.D., Crook, R., Worrall, B.B., Kissela, B., Brown, W.M.,  
846 Rich, S.S., Case, L.D., Evans, E.W., Hague, S., Singleton, A., Hardy, J., SWISS Study  
847 Group, ISGS Study Group, MSGD Study Group, 2005. Phosphodiesterase 4D and 5-  
848 lipoxigenase activating protein in ischemic stroke. *Ann. Neurol.* 58, 351–361.
- 849 Michel, M.C., Rascher, W., 1995. Neuropeptide Y: a possible role in hypertension? *J.*  
850 *Hypertens.* 13, 385–395.
- 851 Mizuno, T., Makino, M., Fujiwara, Y., Nagura, J., Shiga, K., Yoshikawa, K., Nakajima, K.,  
852 Nakagawa, M., 2003. Renin-angiotensin system gene polymorphism in Japanese  
853 stroke patients. *Int. Congr. Ser.* 1252, 83–90.
- 854 Molvarec, A., Széplaki, G., Kovács, M., Széplaki, Z., Fazakas, A., Prohászka, Z., Füst, G.,  
855 Karádi, I., 2007. Estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms  
856 in ischemic stroke in a Hungarian population. *Clin. Chim. Acta* 382, 100–105.
- 857 Munshi, A., Shehnaaz, S., Kaul, S., Reddy, B.P., Alladi, S., Jyothy, A., 2008. Angiotensin  
858 converting enzyme insertion/deletion polymorphism and the risk of ischemic stroke  
859 in a South Indian population. *J. Neurol. Sci.* 272, 132–135.
- 860 Munshi, A., Aliya, N., Jyothy, A., Kaul, S., Alladi, S., Shafi, G., 2009a. Prothombin gene  
861 G20210A mutation is not a risk factor for ischemic stroke in a South Indian  
862 Hyderabad population. *Thromb. Res.* 124, 245–247.
- 863 Munshi, A., Babu, M.S., Kaul, S., Shafi, G., Anila, A.N., Alladi, S., Jyothy, A., 2009b. Phospho-  
864 diesterase 4D (PDE4D) gene variants and the risk of ischemic stroke in a South Indian  
865 population. *J. Neurol. Sci.* 285, 142–145.
- 866 Munshi, A., Sharma, V., Kaul, S., Rajeshwar, K., Babu, M.S., Shafi, G., Anila, A.N., Balakrishna,  
867 N., Alladi, S., Jyothy, A., 2010a. Association of the -344C/T aldosterone synthase  
868 (CYP11B2) gene variant with hypertension and stroke. *J. Neurol. Sci.* 296, 34–38.
- 869 Munshi, A., Rajeshwar, K., Kaul, S., Chandana, E., Shafi, G., Anila, A.N., Balakrishna, N.,  
870 Alladi, S., Jyothy, A., 2010b. VNTR polymorphism in intron 4 of the eNOS gene and  
871 the risk of ischemic stroke in a South Indian population. *Brain Res. Bull.* 82, 247–250.
- 872 Munshi, A., Rajeshwar, K., Kaul, S., Al-Hazzani, A., Alshatwi, A.A., Babu, M.S., Usha,  
873 A., Jyothy, A., 2010c. Interleukin-10-1082 promoter polymorphism and ischemic  
874 stroke risk in a South Indian population. *Cytokine* 52, 221–224.
- 875 Munshi, A., Sharma, V., Kaul, S., Al-Hazzani, A., Alshatwi, A.A., Manohar, V.R., Rajeshwar, K.,  
876 Babu, M.S., Jyothy, A., 2010d. Estrogen receptor  $\alpha$  genetic variants and the risk of  
877 stroke in a South Indian population from Andhra Pradesh. *Clin. Chim. Acta* 411,  
878 1817–1821.
- 879 Munshi, A., Rajeshwar, K., Kaul, S., Al-Hazzani, A., Alshatwi, A.A., Shafi, G., Balakrishna, N.,  
880 Jyothy, A., 2011. Association of tumor necrosis factor- $\alpha$  and matrix metalloproteinase-  
881 3 gene variants with stroke. *Eur. J. Neurol.* 18, 1053–1059.
- 882 Munshi, A., Babu, M.S., Kaul, S., Rajeshwar, K., Balakrishna, N., Jyothy, A., 2012a. Associa-  
883 tion of LPL gene variant and LDL, HDL, VLDL cholesterol and triglyceride levels with  
884 ischemic stroke and its subtypes. *J. Neurol. Sci.* 318, 51–54.
- 885 Munshi, A., Sharma, V., Kaul, S., Al-Hazzani, A., Alshatwi, A.A., Shafi, G., Rajeshwar, K.,  
886 Babu, M.S., Jyothy, A., 2012b. Association of 1347G/A cytochrome P450 4F2  
887 (CYP4F2) gene variant with hypertension and stroke. *Mol. Biol. Rep.* 39, 1677–1682.
- 888 Munshi, A., Roy, S., Thangaraj, K., Kaul, S., Babu, M.S., Jyothy, A., 2012c. Association of  
889 SNP41, SNP56 and a novel SNP in PDE4D gene with stroke and its subtypes. *Gene*  
890 *506*, 31–35.
- 891 Nagase, H., Woessner, J.F., 1999. Matrix metalloproteinases. *J. Biol. Chem.* 274,  
892 21491–21494.
- 893 Pera, J., Slowik, A., Dziedzic, T., Wloch, D., Szczudlik, A., 2006. ACE I/D polymorphism in  
894 different etiologies of ischemic stroke. *Acta Neurol. Scand.* 114, 320–322.
- 895 Perini, F., Morra, M., Alecci, M., Galloni, E., Marchi, M., Toso, V., 2001. Temporal profile of  
896 serum anti-inflammatory and pro-inflammatory interleukins in acute ischemic  
897 stroke patients. *Neurol. Sci.* 22, 289–296.
- 898 Pi, Y., Zhang, L.L., Chang, K., Guo, L., Liu, Y., Li, B.H., Cao, X.J., Liao, S.Q., Gao, C.Y., Li, J.C.,  
899 2013. Lack of an association between CYP11B2 C-344T gene polymorphism and is-  
900 chemic stroke: a meta-analysis of 7,710 subjects. *PLoS One* 8, e68842.
- 901 Rao, R.M., Haskard, D.A., Landis, R.C., 2002. Enhanced recruitment of Th2 and CLA-  
902 negative lymphocytes by the S128R polymorphism of E-selectin. *J. Immunol.* 169,  
903 5860–5865.

- Rao, R., Tah, V., Casas, J.P., Jingerani, A., Whittaker, J., Smeeth, L., Sharma, P., 2009. Ischaemic stroke subtypes and their genetic basis: a comprehensive meta-analysis of small and large vessel stroke. *Eur. Neurol.* 61, 76–86.
- Rees, D.C., Chapman, N.H., Webster, M.T., Guerreiro, J.F., Rochette, J., Clegg, J.B., 1999. Born to clot: the European burden. *Br. J. Haematol.* 105, 564–566.
- Roy, S., Das, S., Danaboina, R., Sharma, V., Kaul, S., Jyothy, A., Munshi, A., 2014. Association of E-selectin gene polymorphism (S128R) with ischemic stroke and stroke subtypes. *Inflammation* 37, 599–603.
- Ruiz-Ortega, M., Lorenzo, O., Ruperez, M., Esteban, V., Suzuki, Y., Mezzano, S., Plaza, J.J., Egido, J., 2001. Role of the renin-angiotensin system in vascular diseases. *Hypertension* 38, 1382–1387.
- Saidi, S., Zammiti, W., Slamia, L.B., Ammou, S.B., Almawi, W.Y., Mahjoub, T., 2009. Interaction of angiotensin-converting enzyme and apolipoprotein E gene polymorphisms in ischemic stroke involving large-vessel disease. *J. Thromb. Thrombolysis* 27, 68–74.
- Saidi, S., Mahjoub, T., Almawi, W.Y., 2010. Aldosterone synthase gene (CYP11B2) promoter polymorphism as a risk factor for ischaemic stroke in Tunisian Arabs. *J. Renin-Angiotensin-Aldosterone Syst.* 11, 180–186.
- Schubert, P., Morino, T., Miyazaki, H., Ogata, T., Nakamura, Y., Marchini, C., Ferroni, S., 2000. Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. *Ann. N. Y. Acad. Sci.* 903, 24–33.
- Sharma, V., Dadheech, S., Kaul, S., Jyothy, A., Munshi, A., 2013. Association of ALOX5AP1 SG13S114T/A variant with ischemic stroke, stroke subtypes and aspirin resistance. *J. Neurol. Sci.* 331, 108–113.
- Shearman, A.M., Cooper, J.A., Kotwinski, P.J., Humphries, S.E., Mendelsohn, M.E., Housman, D.E., Miller, G.J., 2005. Estrogen receptor  $\alpha$  gene variation and the risk of stroke. *Stroke* 36, 2281–2282.
- Shimo-Nakanishi, Y., Urabe, T., Hattori, N., Watanabe, Y., Nagao, T., Yokochi, M., Hamamoto, M., Mizuno, Y., 2001. Polymorphism of the lipoprotein lipase gene and risk of atherothrombotic cerebral infarction in the Japanese. *Stroke* 32, 1481–1486.
- Slowik, A., Turaj, W., Dziedzic, T., Haefele, A., Pera, J., Malecki, M.T., Glodzik-Sobanska, L., Szermer, P., Figlewicz, D.A., Szczudlik, A., 2004. DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. *Neurology* 63, 359–361.
- Spanbroek, R., Grabner, R., Lotzer, K., Hildner, M., Urbach, A., Ruhling, K., Moos, M.P., Kaiser, B., Cohnert, T.U., Wahlers, T., Zieske, A., Plenz, G., Robenek, H., Salbach, P., Kuhn, H., Radmark, O., Samuelsson, B., Habenicht, A.J., 2003. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. *Proc. Natl. Acad. Sci. U. S. A.* 100, 1238–1243.
- Stagliano, N.E., Dietrich, W.D., Prado, R., Green, E.J., Busto, R., 1997. The role of nitric oxide in the pathophysiology of thromboembolic stroke in the rat. *Brain Res.* 759, 32–40.
- Sun, X., Lai, R., Li, J., Luo, M., Wang, Y., Sheng, W., 2013. The -751C/T polymorphism in the TPA gene and ischemic stroke risk: a meta-analysis. *PLoS One* 8, e53558.
- Tao, H.M., Shao, B., Chen, G.Z., 2009. Meta-analysis of the ACE gene polymorphism in cerebral infarction. *Can. J. Neurol. Sci.* 36, 20–25.
- They-They, T.P., Nadifi, S., Rafai, M.A., Battas, O., Slassi, I., 2011. Methylenehydrofolate reductase (C677T) polymorphism and large artery ischemic stroke subtypes. *Acta Neurol. Scand.* 123, 105–110.
- They-They, T.P., Battas, O., Slassi, I., Rafai, M.A., Katumbay, D.T., Nadifi, S., 2012. Prothrombin G20210A and factor V Leiden polymorphisms in stroke. *J. Mol. Neurosci.* 46, 210–216.
- Wang, X.L., Mahaney, M.C., Sim, A.S., Wang, J., Wang, J., Blangero, J., Almasy, L., Badenhop, R.B., Wilcken, D.E., 1997. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. *Arterioscler. Thromb. Vasc. Biol.* 17, 3147–3153.
- Wang, J., Dudley, D., Wang, X.L., 2002. Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. *Arterioscler. Thromb. Vasc. Biol.* 22, e1–e4.
- Wei, Q., Doris, P.A., Pollizotto, M.V., Boerwinkle, E., Jacobs Jr., D.R., Siscovick, D.S., Fornage, M., 2007. Sequence variation in the soluble epoxide hydrolase gene and subclinical coronary atherosclerosis: Interaction with cigarette smoking. *Atherosclerosis* 190, 26–34.
- Weisberg, I., Tran, P., Christensen, B., Sibani, S., Rozen, R., 1998. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. *Mol. Genet. Metab.* 64, 169–172.
- Wiklund, P.G., Nilsson, L., Ardnor, S.N., Eriksson, P., Johansson, L., Stegmayr, B., Hamsten, A., Holmberg, D., Asplund, K., 2005. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. *Stroke* 36, 1661–1665.
- Woo, D., Kaushal, R., Kissela, B., Sekar, P., Wolujewicz, M., Pal, P., Alwell, K., Haverbusch, M., Ewing, I., Miller, R., Kleindorfer, D., Flaherty, M., Chakraborty, R., Deka, R., Broderick, J., 2006. Association of phosphodiesterase 4D with ischemic stroke: a population based case-control study. *Stroke* 37, 371–376.
- Worrall, B.B., Mychaleckyj, J.C., 2006. PDE4D and stroke: a real advance or a case of the Emperor's new clothes? *Stroke* 37, 1955–1957.
- Xu, E., Li, W., Zhan, L., Guan, G., Wang, X., Chen, S., Shi, Y., 2008. Polymorphisms of the lipoprotein lipase gene are associated with atherosclerotic cerebral infarction in the Chinese. *Neuroscience* 155, 403–408.
- Yan, G., Wang, Y., 2012. Association of CYP11B2 gene polymorphism with ischemic stroke in the north Chinese Han population. *Neurol. India* 60, 504–509.
- Yi, P., Melnyk, S., Pogribna, M., Pogribny, I.P., Hine, R.J., James, S.J., 2000. Increase in plasma homocysteine associated with parallel increases in plasma S-adenosyl homocysteine and lymphocyte DNA hypomethylation. *J. Biol. Chem.* 275, 29318–29323.
- Zhang, Y., Xie, R., Wang, Y., Chen, D., Wang, G., Xu, X., 2002. Association of estrogen receptor gene polymorphism with cerebral infarction, a case-control study. *Zhonghua Yi Xue Za Zhi* 82, 1443–1446.
- Zhang, S.Y., Xu, M.L., Zhang, C.E., Qu, Z.Y., Zhang, B.B., Zheng, Z.Y., Zhang, L.M., 2012. Association of ALOX5AP gene single nucleotide polymorphisms and cerebral infarction in the Han population of northern China. *BMC Med. Genet.* 13, 61.
- Zhao, N., Liu, X., Wang, Y., Liu, X., Li, J., Yu, L., Ma, L., Wang, S., Zhang, H., Liu, L., Zhao, J., Wang, X., 2012. Association of inflammatory gene polymorphisms with ischemic stroke in a Chinese Han population. *J. Neuroinflammation* 9, 162.
- Zhao, J., Zheng, L., Fei, Q., Fu, Y., Weng, Y., Wu, H., Li, H., Jun, Q., Shao, J., Xu, Y., 2013. Association of thromboxane A2 receptor gene polymorphisms with cerebral infarction in a Chinese population. *Neurol. Sci.* 34, 1791–1796.